LT4076461T - Lumateperonas, skirtas panaudoti šizofrenijos gydymui - Google Patents

Lumateperonas, skirtas panaudoti šizofrenijos gydymui

Info

Publication number
LT4076461T
LT4076461T LTEPPCT/US2020/066224T LTUS2020066224T LT4076461T LT 4076461 T LT4076461 T LT 4076461T LT US2020066224 T LTUS2020066224 T LT US2020066224T LT 4076461 T LT4076461 T LT 4076461T
Authority
LT
Lithuania
Prior art keywords
lumateperone
schizophrenia treatment
schizophrenia
treatment
Prior art date
Application number
LTEPPCT/US2020/066224T
Other languages
English (en)
Lithuanian (lt)
Inventor
Robert E. Davis
Kimberly Vanover
Original Assignee
Intra-Cellular Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra-Cellular Therapies, Inc. filed Critical Intra-Cellular Therapies, Inc.
Publication of LT4076461T publication Critical patent/LT4076461T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2020/066224T 2019-12-19 2020-12-18 Lumateperonas, skirtas panaudoti šizofrenijos gydymui LT4076461T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962950828P 2019-12-19 2019-12-19
PCT/US2020/066224 WO2021127572A1 (en) 2019-12-19 2020-12-18 Methods of schizophrenia treatment

Publications (1)

Publication Number Publication Date
LT4076461T true LT4076461T (lt) 2026-06-25

Family

ID=76437353

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2020/066224T LT4076461T (lt) 2019-12-19 2020-12-18 Lumateperonas, skirtas panaudoti šizofrenijos gydymui

Country Status (14)

Country Link
US (1) US20210186962A1 (cg-RX-API-DMAC7.html)
EP (2) EP4744678A3 (cg-RX-API-DMAC7.html)
JP (2) JP7727634B2 (cg-RX-API-DMAC7.html)
DK (1) DK4076461T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067760T3 (cg-RX-API-DMAC7.html)
FI (1) FI4076461T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260406T1 (cg-RX-API-DMAC7.html)
LT (1) LT4076461T (cg-RX-API-DMAC7.html)
PL (1) PL4076461T3 (cg-RX-API-DMAC7.html)
PT (1) PT4076461T (cg-RX-API-DMAC7.html)
RS (1) RS67890B1 (cg-RX-API-DMAC7.html)
SI (1) SI4076461T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600134T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021127572A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428506B2 (en) 2012-04-14 2016-08-30 Intra-Cellular Therapies, Inc. Substituted pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines for the treatment of nervous system disorders
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
SMT202600133T1 (it) 2018-03-23 2026-05-12 Intra Cellular Therapies Inc Composti organici
AU2019328528B2 (en) 2018-08-31 2025-01-23 Intra-Cellular Therapies, Inc. Novel methods
JP2022549335A (ja) 2019-09-25 2022-11-24 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規方法
IL297333B2 (en) * 2020-04-17 2025-09-01 Honeybrains Llc Preparations and methods for treating neuropsychiatric disorders
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000077001A1 (en) 1999-06-15 2000-12-21 Du Pont Pharmaceuticals Company Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
MX394214B (es) 2007-03-12 2025-03-24 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
CA2719824A1 (en) * 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
ES2530090T3 (es) 2008-03-12 2015-02-26 Intra-Cellular Therapies, Inc. Sólido de gamma-carbolinas fusionadas con heterociclo sustituido
CA2725342C (en) 2008-05-27 2024-02-20 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for sleep disorders and other disorders
KR102967223B1 (ko) * 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
KR20220054908A (ko) 2014-04-04 2022-05-03 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP7013454B2 (ja) * 2016-10-12 2022-02-15 イントラ-セルラー・セラピーズ・インコーポレイテッド アモルファス固体分散体
CA3082834A1 (en) * 2017-11-22 2019-05-31 Concert Pharmaceuticals, Inc. Deuterated analogs of d-serine and uses thereof
WO2019102240A1 (en) * 2017-11-27 2019-05-31 Egis Gyógyszergyár Zrt. Method for the manufacture of lumateperone and its salts
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
WO2020047408A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
WO2020112941A2 (en) * 2018-11-27 2020-06-04 Teva Czech Industries S.R.O Solid state forms of lumateperone salts and processes for preparation of lumateperone and salts thereof

Also Published As

Publication number Publication date
EP4076461A4 (en) 2024-01-03
EP4744678A2 (en) 2026-05-20
JP7727634B2 (ja) 2025-08-21
JP2025166121A (ja) 2025-11-05
HRP20260406T1 (hr) 2026-05-08
JP2023507584A (ja) 2023-02-24
EP4744678A3 (en) 2026-07-22
DK4076461T3 (da) 2026-02-23
WO2021127572A1 (en) 2021-06-24
EP4076461B1 (en) 2026-01-28
PL4076461T3 (pl) 2026-04-27
SI4076461T1 (sl) 2026-05-29
EP4076461A1 (en) 2022-10-26
US20210186962A1 (en) 2021-06-24
RS67890B1 (sr) 2026-04-30
PT4076461T (pt) 2026-04-16
FI4076461T3 (fi) 2026-03-24
SMT202600134T1 (it) 2026-05-12
ES3067760T3 (en) 2026-05-25